Kestrel

NEYPPC Pharmacy - ULM Aseptic Compounded Specials

Leeds Teaching Hospitals NHS Trust · published Wed 23 Sep 2026

In plain English

Reading the notice and writing a summary. This takes a few seconds the first time.

Who holds it now

Last won by Clinigen Healthcare Limited and Mawdsley-Brooks & Co Ltd and Durbin PLC and 4 more in Mar 2026, for £27.4m.

What you're up against

  • The same firms have won it the last 2 times Kestrel found: expect them to bid again, and to know the work well.
  • 8 different firms won this buyer's 2 awards for this kind of work in 2026.
  • It last went for £27.4m in 2026.
  • The last award named 7 suppliers: it may be a framework, where many firms are chosen.

From Leeds Teaching Hospitals NHS Trust's earlier award notices for the same kind of work. The tender documents usually say which contract this one replaces.

The notice doesn't say where the documents are, but Leeds Teaching Hospitals NHS Trust's other tenders use health-family.force.com. Register there (it's free) and look for this tender, or email the buyer's contact on the notice.

The notice as published

The North East and Yorkshire NHS Pharmaceutical Purchasing Consortium intends to establish a Framework Agreement for the supply of Unlicensed Aseptic Compounded Specials. The requirement will cover the provision of unlicensed aseptic compounded specials, including sterile ready-to-administer injectable and infusion products that are batch manufactured or otherwise aseptically prepared in accordance with applicable UK regulatory standards and Good Manufacturing Practice (GMP) requirements. Suppliers will be required to hold all relevant licences, authorisations and regulatory approvals necessary to manufacture and supply unlicensed medicines within the UK, together with the appropriate quality assurance and batch release arrangements. The Framework Agreement will provide participating NHS organisations with access to safe, compliant and competitively sourced unlicensed aseptic compounded products, supporting continuity of supply, product quality assurance, patient safety and value for money across the NHS.